OPN5 and B-cell chronic lymphocytic leukemia: Additionally, we show that pharmacological BET inhibition with OPN5 reverses MDSC-mediated immune suppression in preclinical models of CLL, highlighting the translational potential of BET inhibition as an anti-cancer therapeutic simultaneously targeting MDSCs in CLL.